Drug Profile
Meningococcal vaccine group B - Children's Hospital & Research Center at Oakland
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Childrens Hospital of Oakland
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Meningococcal group B infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Meningococcal-group-B-infections in USA
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche
- 17 Jan 2005 Preclinical trials in Meningococcal group B infections in USA (unspecified route)